Post-Market Drug Surveillance Research Methods Are Focus Of Reagan-Udall Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The Reagan-Udall Foundation has established an organizing committee to help inform the design and structure of what its Innovation in Medical Evidence Development and Surveillance program’s post-market research methods should look like and develop the IMEDS charter.
You may also be interested in...
Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA
A pilot project operated by the Reagan-Udall Foundation and funded by Pfizer will evaluate ways drug companies can use FDA’s Sentinel electronic data network to conduct independent post-market safety surveillance.
Reagan-Udall, Still Waiting For FDA Funding, Studies Drug Toxicity Pathways
Created by Congress to help FDA modernize medical product development and evaluation, the foundation will receive its first influx of federal money to support overhead in fiscal 2012.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.